Introduction
Few commodities expose the contradictions of modern capitalism as starkly as painkillers. They sit at the junction of compassion and commerce: a promise to relieve suffering, packaged, priced, shipped, advertised, and regulated. Markets of Pain: Opium, Capitalism, and the Global History of Painkillers by Benjamin Robert Siegel arrives amid renewed scrutiny of opioids worldwide, inviting readers to see today’s crises not as aberrations but as episodes in a longer economic history of drug markets. The story of opium and its derivatives is, in important ways, a story of how global trade, finance, empire, and industrial science learned to turn bodily vulnerability into steady demand—and how states repeatedly struggled to govern that demand.
Historical context: from imperial opium to industrial pharmaceuticals
Opium was a major long-distance commodity well before the age of factories, but the nineteenth century made it central to the architecture of global political economy. The best-known inflection point came with the Opium Wars (1839–42 and 1856–60), when Britain fought to force open Chinese markets and protect an opium trade linked to imperial revenues and commercial balance. The trade was not just about smugglers and consumers; it was embedded in the fiscal machinery of empire. In British India, opium production and auction systems became a pillar of colonial finance, illustrating a recurring theme: states often profited from narcotics even while deploring their social costs.
The late nineteenth and early twentieth centuries brought a second transformation: industrial chemistry and branded medicines. The isolation of morphine in the early 1800s and the later introduction of heroin as a pharmaceutical product reflected a broader shift from plant-based materia medica toward standardized, factory-produced drugs. This industrial turn mattered economically. It enabled quality control, scalable manufacturing, and global branding—features that made pain relief not merely a local practice but a modern consumer market. It also gave new leverage to firms able to combine chemistry, patents or trade secrets, distribution networks, and advertising.
Alongside this growth, international controls emerged. The early twentieth century saw an expanding regime of narcotics regulation, pressed by states worried about public health, social order, and diplomatic tensions. Regulation did not end markets; it restructured them—diverting some demand into licit medical channels while shifting other demand into illicit supply chains, where profits could rise with risk.
Main analysis: how capitalism built—and repeatedly rebuilt—markets for pain relief
A global economic history of painkillers is ultimately about three interlocking dynamics: demand formation, supply-chain power, and the politics of legitimacy.
First, demand for pain relief is unusually reliable—yet highly shapeable. Pain is universal, but how societies interpret and treat it is historically contingent. Commercial medicine repeatedly expanded the definition of treatable pain and broadened the pool of “appropriate” consumers. In the nineteenth century, patent medicines and widely marketed remedies offered self-medication to customers who might never see a physician. In the twentieth century, hospital medicine, surgery, and later mass insurance systems altered expectations of pain-free recovery. The economic principle is straightforward: when consumers come to see relief as a right rather than a contingency, demand becomes less price-sensitive and more politically charged.
Second, the supply side rewarded actors who could manage risk—whether legal, logistical, or reputational. In imperial opium, the key capabilities included territorial control, taxation, shipping, and the coercive enforcement of trade access. In industrial pharmaceuticals, advantage flowed to firms that could finance laboratories, navigate regulation, secure market access through doctors and hospitals, and sustain marketing campaigns. In illicit markets, different capabilities dominate: concealment, corruption, violence, and flexible routing. Across all these forms, painkillers demonstrate how capitalism does not simply “trade goods”; it builds institutions that make some exchanges legitimate and others punishable—often with uneven consequences across regions and classes.
Third, the history is inseparable from the state—both as regulator and market-maker. Governments taxed opium, licensed medical supply, criminalized nonmedical use, and used policing to define who counted as a patient versus a deviant. Regulation frequently lagged innovation. New formulations, new delivery systems, and new marketing techniques routinely outran existing rules, producing cycles familiar to economic historians: expansion, scandal, tightening, circumvention, and renewed expansion under different terms.
Why does this matter? Because the painkiller economy is a case study in how markets handle goods with “dual use”: substances that can be both medicine and source of harm. Standard market mechanisms struggle when consumer choice is shaped by dependence, when information is asymmetric (patients rely on expert intermediaries), and when social costs spill over to families, employers, and public budgets. These are classic conditions for market failure, but the historical record shows that “fixes” can create new distortions—by restricting supply in ways that empower illicit networks, or by liberalizing access in ways that invite aggressive promotion.
Conclusion
Seen in long perspective, the global history of opium and painkillers is not a linear march from vice to medicine or from tradition to science. It is a recurring renegotiation of who deserves relief, who is allowed to sell it, and who bears the costs when relief becomes dependence. That is why Siegel’s subject matters for economic history: it links empire and industry, trade and regulation, corporate strategy and household suffering, in one continuous narrative of capitalism’s capacity to monetize necessity. As today’s governments confront opioid harms while millions still live with untreated pain, the central historical lesson is uncomfortable but clarifying: pain relief is never only a medical question. It is a political economy—built by institutions, incentives, and power.